| Cat. No. |
Product Name |
Information |
| PC-38827 |
Izuralimab
Anti PD1/ICOS bispecific mAb
|
Izuralimab (XmAb 23104, XmAb 104) is a bispecific monoclonal antibody targeting PD1 and ICOS (inducible T-cell costimulator, CD278), potentially resulting in enhanced anti-tumor immune response. |
| PC-38826 |
Idactamab
Anti-SLC1A5 mAb
|
Idactamab is an anti-human SLC1A5 monoclonal antibody (mAb). Isotype: IgG1-kappa. Anti-[human SLC1A5 (solute carrier family 1 member 5,neutral amino acid
transporter, RDRC, M7V1,AAAT, ASCT2)], human monoclonal antibody. |
| PC-38825 |
Grisnilimab
Anti-CD7 mAb
|
Grisnilimab is an anti-CD7 mAb. Isotype: IgG2A-lambda. Anti-[CD7 (CD7 antigen (p41),GP40, LEU-9, TP41, Tp40)], mouse monoclonal antibody. |
| PC-38824 |
Geptanolimab
Anti-PD-1 mAb
|
Geptanolimab (GB226) is a fully humanized programmed cell death protein 1 (PD-1, CD279) antibody, inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response. |
| PC-38823 |
Garivulimab
Anti-PD-L1 mAb
|
Garivulimab (BGB A333) is a humanised IgG1-variant monoclonal antibody against programmed cell death 1-ligand 1 (PD-L1) for treatment of various cancer. |
| PC-38822 |
Favezelimab
Anti-LAG3 mAb
|
Mavezelimab (Favezelimab, MK-4280) is a humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. |
| PC-38821 |
Etevritamab
EGFRvIII/CD3 BiTE
|
Etevritamab (AMG 596) is an EGFRvIII x CD3 bispecific T-cell engager (BiTE), AMG 596 is composed of two single-chain variable fragments that simultaneously bind to the tumor-specific antigen EGFR variant III (EGFRvIII) on GBM cells and to CD3 on T cells. |
| PC-38820 |
Enibarcimab
Anti-Adrenomedullin mAb
|
Enibarcimab (HAM8101, Adrecizumab) is a humanized, non-neutralizing anti-adrenomedullin monoclonal antibody, shows promising results in sepsis shock models. |
| PC-38819 |
Emerfetamab
CD33/CD3 BiTE
|
Emerfetamab (AMG 673) is a half-life extended anti-CD33 x anti-CD3 BiTE (bispecific T cell engager) antibody with potential for AML treatment. |
| PC-38818 |
Eluvixtamab
CD33/CD3 BiTE
|
Eluvixtamab (AMG 330) is a CD33/CD3 bispecific T-cell engager (BiTE) antibody, shows potent CD33-dependent cytolytic activity in vitro and anti-AML activity in vivo. |
| PC-38817 |
Ebronucimab
Anti-PCSK9 mAb
|
Ebronucimab (AK109) is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) with potential for the treatment of primary hyperlipidemias, including homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH) and other primary hypercholesterolemia. |
| PC-38816 |
Divozilimab
Anti-CD20 mAb
|
Divozilimab (BCD-132 is a humanised monoclonal antibody against CD20 for the treatment of multiple sclerosis. |
